Hepatology International最新文献_第6页

Long-term survival benefit of atezolizumab/bevacizumab treatment in unresectable HCC patients. atezolizumab/bevacizumab治疗不可切除HCC患者的长期生存获益

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-27 DOI: 10.1007/s12072-025-10918-z

Markus Peck-Radosavljevic

引用次数: 0

Critique of CSPH impact on HCC surgical outcomes. CSPH对HCC手术结果影响的评论。

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-26 DOI: 10.1007/s12072-025-10915-2

Yuwei Zhao, Shenglong Li

引用次数: 0

Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator? 重组人血清白蛋白：真正的治疗替代品还是仅仅是血清水平的提升？

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-19 DOI: 10.1007/s12072-025-10902-7

Junze Dai, Xudong Zhu, Yefu Liu

引用次数: 0

Propranolol versus endoscopic variceal ligation for primary prophylaxis of esophageal varices in cirrhosis: a systematic review and meta-analysis of randomized controlled trials. 心得安与内窥镜下静脉曲张结扎对肝硬化食管静脉曲张的初级预防：随机对照试验的系统回顾和荟萃分析。

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-19 DOI: 10.1007/s12072-025-10903-6

Leonardo Corrêa Süffert, Luis Pedro Possapp Beis, Isabella Heringer Padilha, Henrique Steffens de Abreu, Jesuély Spieckert de Souza, Victor Alves Galvão, Frederico Friedrich, Marcelo Campos Appel da Silva

{"title":"Propranolol versus endoscopic variceal ligation for primary prophylaxis of esophageal varices in cirrhosis: a systematic review and meta-analysis of randomized controlled trials.","authors":"Leonardo Corrêa Süffert, Luis Pedro Possapp Beis, Isabella Heringer Padilha, Henrique Steffens de Abreu, Jesuély Spieckert de Souza, Victor Alves Galvão, Frederico Friedrich, Marcelo Campos Appel da Silva","doi":"10.1007/s12072-025-10903-6","DOIUrl":"https://doi.org/10.1007/s12072-025-10903-6","url":null,"abstract":"Background: Several studies have shown similar efficacy between nonselective beta-blockers (NSBBs) and endoscopic variceal ligation (EVL) in preventing esophageal variceal bleeding in cirrhosis. However, the comparative effectiveness between propranolol (PPL) and EVL remains uncertain. This meta-analysis evaluated both strategies.Methods: PubMed, Embase, and Cochrane Central were searched for randomized-controlled trials (RCTs) comparing PPL and EVL for primary prophylaxis of esophageal variceal bleeding in cirrhotic patients. Outcomes were evaluated using risk ratios (RR) with 95% confidence intervals (CI), and heterogeneity was assessed by the I2 statistic. Meta-regressions were conducted based on Child-Pugh classification and presence of ascites. All statistical analyses were performed using RStudio version 4.4.2.Results: Fourteen RCTs were included, comprising 1345 patients: 664 (49.4%) received EVL and 681 (50.6%) PPL. EVL was more effective in preventing esophageal variceal hemorrhage (RR: 1.40; 95% CI: 1.02-1.91; p = 0.035; I2 = 8.5%). No differences were found in variceal bleeding-related deaths (RR: 1.28; 95% CI: 0.76-2.15; p = 0.351; I2 = 0%), all-cause mortality (RR: 0.93; 95% CI: 0.76-1.14; p = 0.503; I2 = 0%), or in the incidence of adverse events (RR: 1.20; 95% CI: 0.59-2.46; p = 0.612; I2 = 84.7%).Conclusion: EVL was superior in preventing esophageal variceal bleeding. Such results suggest that not all NSBBs provide equivalent efficacy in primary prophylaxis, reinforcing the need for further studies to confirm these findings.","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resection in HCC and cirrhosis: linking clinical relevance to improved outcomes. 肝细胞癌和肝硬化的切除：将临床相关性与改善预后联系起来。

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-18 DOI: 10.1007/s12072-025-10913-4

Daniel Maluf, Raphael Meier, Valeria R Mas

引用次数: 0

Comparison of the impact of shunting the left versus right portal vein branch during TIPS on the postoperative overt hepatic encephalopathy: a randomized trial. TIPS术中门静脉左支与右支分流对术后肝性脑病影响的比较：一项随机试验。

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-18 DOI: 10.1007/s12072-025-10908-1

Yongjie Zhou, Jingqin Ma, Yaozu Liu, Li Ma, Jiaze Yu, Minjie Yang, Zhiping Yan, Wen Zhang, Jianjun Luo

{"title":"Comparison of the impact of shunting the left versus right portal vein branch during TIPS on the postoperative overt hepatic encephalopathy: a randomized trial.","authors":"Yongjie Zhou, Jingqin Ma, Yaozu Liu, Li Ma, Jiaze Yu, Minjie Yang, Zhiping Yan, Wen Zhang, Jianjun Luo","doi":"10.1007/s12072-025-10908-1","DOIUrl":"https://doi.org/10.1007/s12072-025-10908-1","url":null,"abstract":"Background and aim: The effect of shunting the left or right branch of the portal vein on the post-transjugular intrahepatic portosystemic shunt (TIPS) hepatic encephalopathy (HE) remains controversial. Therefore, we designed this prospective, randomized, single-blinded trial to compare the incidence of HE after shunting the left or right branch of the portal vein during TIPS in cirrhotic patients to prevent variceal rebleeding.Methods: Consecutive patients diagnosed with hepatitis B virus (HBV)-related cirrhosis were randomly assigned in a 1:1 ratio to undergo the TIPS procedure, with the shunt directed to either the left or right branch of the portal vein. The primary outcome was the incidence of overt HE within 2 years. The secondary outcomes included shunt dysfunction, variceal rebleeding, survival, adverse events, and changes in liver function.Results: Between June 2019 and December 2020, 130 patients were randomly divided into two groups (left branch group vs right branch group). The 2-year cumulative incidence rates of free overt HE in the left branch group did not demonstrate statistical superiority over the right branch group (78.5% vs 68.6%, respectively; p = 0.236, HR = 1.49, 95% CI 0.76-2.93). Similarly, no statistical differences were observed in stent patency, all-cause bleeding, survival, or adverse events.Conclusion: Compared to shunting the right branch of the portal vein, shunting the left branch during TIPS placement did not impact the incidence of post-TIPS HE and other clinical outcomes in cirrhotic patients to prevent variceal rebleeding. The choice of puncture site should be primarily guided by the patient's liver anatomy and the operator's experience.","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comments on: CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study. 基于ct的肿瘤内和肿瘤周围放射组学预测肝动脉输注化疗联合lenvatinib和PD-1在高危肝癌患者中的治疗反应：一项多中心研究。

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-17 DOI: 10.1007/s12072-025-10909-0

Meng-Yuan Shen, Ze-Jiong Li, Dan-Dan Feng, Jian-Nong Wu

引用次数: 0

Enhancing the prognostic value of inflammatory markers in hepatocellular carcinoma: a thoughtful discussion. 增强肝细胞癌炎症标志物的预后价值：一个深思熟虑的讨论。

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-16 DOI: 10.1007/s12072-025-10910-7

Cong Liu, Ying Bai

引用次数: 0

Commentary on "USP13 promotes hepatic stellate cells activation and aggravates liver fibrosis through deubiquitinating SMAD3". 点评“USP13通过去泛素化SMAD3促进肝星状细胞活化，加重肝纤维化”

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-16 DOI: 10.1007/s12072-025-10911-6

Meng-Yuan Shen, Yi-Heng Fu, Jian-Nong Wu

引用次数: 0

Comment on "CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study". 评论“基于ct的肿瘤内和肿瘤周围放射组学预测肝动脉输注化疗联合lenvatinib和PD-1治疗高危肝癌的疗效：一项多中心研究”。

IF 6.1 2区医学

Hepatology International Pub Date : 2025-09-15 DOI: 10.1007/s12072-025-10912-5

Zhiyao Shi, Kai Feng, Yu Gao, Xixing Wang

引用次数: 0